Amarantus Announces Positive Preclinical Data on the Effects of MANF on Vision in a Model of Retinitis Pigmentosa Nov. 25, 2014 Amarantus to Present at the LD Micro Main Event VII Investor Conference on December 2, 2014 Live Webcast of Presentation on Tuesday, December 2, 2014 at 10:30 a.m. PST / 1:30 p.m. EST - Nov. 24, 2014 Amarantus Completes Enrollment of Expanded LP-002 Study of Alzheimer's Blood Diagnostic LymPro Test(R) to Assess Predictive Value in Early-Stage Disease Nov. 20, 2014 Astute Deal Brings In Another Shot On Goal For Amarantus Bio By Jason Napodano, CFA - November 19, 2014 Regenicin Enters Into Asset Purchase Agreement with Amarantus Bioscience Holdings, Inc. Nov 19, 2014 12:46 p.m. Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza Nov 17, 2014 4:20 p.m. Amarantus to Host Business Update Conference Call on November 18, 2014 Nov 17, 2014 8:02 a.m. Amarantus Reports Third Quarter 2014 Financial Results and Enters Into Strategic Preferred Financing Nov 10, 2014 6:01 a.m. AMARANTUS BIOSCI INC(OTCMKTS:AMBS) is Making Moves OCTOBER 29, 2014 Eltoprazine, LymPro and MANF: The Path Forward to Value Creation October 27, 2014 8:00 am Amarantus CEO Gerald Commissiong Elected to Biotechnology Industry Organization Committees Oct 20, 2014 8:01 a.m. Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa Also in Cramer's Portfolio: Amarantus Applies To FDA For MANF Orphan Drug Designation In Retinitis Pigmentosa Oct 16, 2014 9:30 a.m. Amarantus Announces Positive LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test(R) Oct 9, 2014 6:01 a.m. Amarantus Investigator Presents Positive MANF Animal Data in Central Retinal Vein Occlusion and Glaucoma at the Targeting Ocular Disorders Conference Oct 7, 2014 8:01 a.m. Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2014-2024 : Opportunities for Leading Companies Oct 1, 2014 9:16 p.m. Amarantus Requests Pre-IND Feedback From FDA for Eltoprazine Phase IIb Parkinson's Disease Levodopa-Induced Dyskinesia Clinical Trial Sept 29, 2014 2:04 p.m.
Amarantus BioScience Holdings, Inc. c/o Janssen Labs @ QB3 953 Indiana Street San Francisco, CA 94107
c/o ICS Corporate Services SA 29 quai du Mont Blanc CH-1201 Geneva Switzerland
email@example.com firstname.lastname@example.org Phone: (408) 737-2734 Fax: (408) 852-4427
Gerald E. Commissiong, President and Chief Executive Officer, will present at the LD Micro Main Event VII micro-cap investor conference being held December 2 - 4, 2014 at the Luxe Sunset Hotel in Los Angeles, California.
Mr. Commissiong will present on Tuesday, December 2, 2014 at 10:30 a.m. PST (1:30 p.m. EST) and will provide an update on Amarantus' recent corporate milestone achievements, clinical development progress and expected near-term catalysts. Amarantus to Present at the LD Micro Main Event VII Investor Conference on December 2, 2014